Fabrazyme Facts
What is Fabrazyme?
Fabrazyme ® (agalsidase beta) is a medication designed to replace the alpha-GAL enzyme, which is missing or insufficient in people with Fabry disease. This type of medication is known as an enzyme replacement therapy (or ERT).
How Does it Work?
People with Fabry disease are missing or have insufficient amounts of the alpha-GAL enzyme. Without enough of this enzyme, a fatty substance called globotriaosylceramide (GL-3) builds up in the cells throughout the body.
Fabrazyme is intended to replace the alpha-GAL enzyme, which breaks down accumulated GL-3. Treatment with Fabrazyme every two weeks may improve the signs and symptoms of Fabry disease, since Fabrazyme has been shown to reduce GL-3 levels in certain cells. The relationship between GL-3 reduction and the improvement of specific signs and symptoms, however, has not been established.
How is Fabrazyme Treatment Given?
Fabrazyme is given by intravenous (IV) infusion, meaning that the medication is infused directly into your bloodstream through a vein. Fabrazyme cannot be taken orally as a pill or liquid because it is an enzyme that would be destroyed in your digestive system. Infusion into the bloodstream bypasses your body’s digestive processes and allows Fabrazyme to go to work in cells throughout the body.
What is the Recommended Dosage?
The recommended dosage of Fabrazyme is 1.0 milligram (mg) for each kilogram (kg) of body weight given once every 2 weeks as an IV infusion. For instance, a man weighing 70 kg (approximately 154 pounds) would receive 70 mg of Fabrazyme.
What are the Possible Side Effects of Fabrazyme?
The most serious and common side effects reported with Fabrazyme are infusion reactions, meaning that they occurred as a result of the infusion. Infusion reactions occurred in many people treated with Fabrazyme, and some of the reactions were severe. Side effects may include: increase in heart rate, increase in blood pressure up to a few hours after infusion, throat tightness, chest pain/tightness, shortness of breath, fever, chills, abdominal pain, itching, hives, nausea, vomiting, lip or ear swelling, rash, decrease in blood pressure, muscle pain and headache.
To reduce the potential for an infusion reaction, your health care provider will give you anti-fever medications (for example, acetaminophen or ibuprofen) before the infusion. Infusion reactions occurred in some people after receiving anti-fever medications, antihistamines, and oral steroids.
Important Safety
Information
Fabrazyme (agalsidase beta) is indicated for use in patients with Fabry
disease. Fabrazyme reduces globotriaosylceramide (GL-3) deposition in
capillary endothelium of the kidney and certain other cell types. The
reduction of GL-3 inclusions suggests that Fabrazyme may ameliorate disease
expression; however, the relationship of GL-3 inclusion reduction to
specific clinical manifestations of Fabry disease has not been established.
The most serious and most common adverse reactions reported with Fabrazyme
are infusion reactions. Serious and/or frequently occurring related adverse
reactions consisted of one or more of the following events: chills, pyrexia,
feeling hot or cold, dyspnea, nausea, flushing, headache, vomiting,
paresthesia, fatigue, pruritus, pain in extremity, hypertension, chest pain,
throat tightness, abdominal pain, dizziness, tachycardia, nasal congestion,
diarrhea, edema peripheral, myalgia, back pain, pallor, bradycardia,
urticaria, hypotension, face edema, rash, and somnolence. The occurrence of
somnolence can be attributed to clinical trial specified pre-treatment with
antihistamines.
Other reported serious adverse events included stroke, pain, ataxia,
bradycardia, cardiac arrhythmia, cardiac arrest, decreased cardiac output,
vertigo, hypoacousia, and nephrotic syndrome. These adverse events also
occur as manifestations of Fabry disease; an alteration in frequency or
severity cannot be determined from the small numbers of patients studied.
Infusion reactions occurred in many patients treated with Fabrazyme and some
of the reactions were severe. Patients should be given antipyretics prior
to infusion. Infusion reactions occurred in some patients after receiving
pretreatment with antipyretics, antihistamines, and oral steroids. Infusion
reactions declined in frequency with continued use of Fabrazyme. However,
infusion reactions may still occur despite extended duration of Fabrazyme
treatment. Because of the potential for severe infusion reactions,
appropriate medical support measures should be readily available when
Fabrazyme is administered.
Patients with compromised cardiac function should be monitored closely if
the decision is made to administer Fabrazyme.
Most patients develop IgG antibodies to Fabrazyme. A few patients developed
IgE or skin test reactivity specific to Fabrazyme. Physicians should
consider testing for IgE in patients who experienced suspected allergic
reactions and consider the risks and benefits of continued treatment in
patients with anti- Fabrazyme IgE. Patients with Fabrazyme- specific IgE
antibody have been treated using a rechallenge protocol. Rechallenge of
these patients should only occur under the direct supervision of qualified
personnel, with appropriate medical support measures readily available.
The safety and efficacy in patients younger than 8 years of age have not
been evaluated. IgE immunologic responses in pediatric patients may differ
from those in adults, as IgG seroconversion was associated with prolonged
half-life concentrations of Fabrazyme, which is rarely observed in adult
patients.
Fabrazyme is available by prescription only. Side effects should be reported
promptly to Genzyme Medical Information at 800-745-4447, option 2. To learn
more, please see the full
prescribing information (PDF) or contact Genzyme at 1-800-745-4447.
|
|
 |
|